Three new #obesity drugshigh dose semaglutide, semaglutide plus cagrilintide, and oral orforglipronmay soon be approved in the US. JAMA Medical News Director Jennifer Abbasi and Lead Senior Staff Writer Rita Rubin examine how Cagrilintide, an amylin analogue, is a promising medication for weight loss by enhancing satiety, delaying gastric emptying, and suppressing appetite. In my patients, I have also seen increased Semaglutide Cagrillintide Blended Peptides for Research & Clinical Trials Oraltide Pharma Clinical trials of subcutaneous tirzepatide, retatrutide, and Download Scientific Diagram Anti Obesity Medications in Patients With Heart Failure: Current Evidence and Practical Guidance Circulation: Heart Failure